Cocrystal Pharma

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication –

Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

Amyris

BIO-key Int.

Everspin Technologies

Old Second Bancorp

Markets are down today, pretty much from the get-go. As investors become increasingly concerned with the worsening coronavirus cases, it's become clear that a sell-off is imminent.

Short Positions To Take Amid Stock Market’s Sharp Decline

Second Sight Medical Products

EyePoint Pharmaceuticals

Recro Pharma

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Top Stocks To Short As Dow Jumps Amid Coronavirus Spikes

Blink Charging

ElectroCore Inc

Tetraphase Pharmaceuticals

With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio with or bet against overall.

Top Stocks To Short As Markets Continue To Fluctuate

Inspired Entertainment

KemPharm

We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.

Top Companies To Short As Stock Market Optimism Dips

DermTech Inc

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified several top shorts for your portfolio.

Top Companies To Short As Stock Market Continues To Rally

-  Company has sufficient capital to advance pipeline and fund operations through 2021 -

Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program –

Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs

- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program -

Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action

- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals -

Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D.

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

BOTHELL, WA, March  30, 2020  (GLOBE NEWSWIRE) --  Cocrystal Pharma, Inc  . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today its financial results for the year ended December 31, 2019, provided its business outlook for 2020 and outlined its expected value-driving milestones.

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

BOTHELL, WA, March  11, 2020  (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 5,037,038 shares of its common stock at a purchase price of $1.35 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $6.8 million, before deducting placement agent fees and offering expenses.

Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market

Gilead Sciences

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

NanoViricides

Novavax

Pfizer

Sanofi

Vaxart

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

BOTHELL, WA, March  09, 2020  (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 5,037,038 shares of its common stock at a price of $1.35 per share, for aggregate gross proceeds of approximately $6.8 million, in a registered direct offering priced at-the-market under Nasdaq rules. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market

AIM ImmunoTech Inc

Spherix

The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and Russia.

3 Biotech Stocks Defying Today's Market Meltdown Thanks To COVID-19 Developments

BOTHELL, WA,, March  06, 2020  (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it has initiated its Coronavirus program.

Cocrystal Pharma Announces Plans to Advance Coronavirus Program

BOTHELL, WA, Feb.  28, 2020  (GLOBE NEWSWIRE) --    COCRYSTAL PHARMA, INC.   (NASDAQ :  COCP )  (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 8,461,540 shares of its common stock at a purchase price of $1.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $11.0 million, before deducting placement agent fees and offering expenses.

Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, Feb.  27, 2020  (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC.  ( NASDAQ: COCP )  (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,461,540 shares of its common stock at a price of $1.30 per share, for aggregate gross proceeds of approximately $11.0 million, in a registered direct offering priced at-the-market under Nasdaq rules. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market

Cocrystal Pharma Inc (NASDAQ: COCP) shares are skyrocketing Monday following a licensing agreement the company reached with the Kansas State University Research Foundation.

Nanocap Biotech Stock Rips 180% Higher On Coronavirus Drug Licensing

     –   Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral diseases, including coronavirus respiratory infections –

Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals

– Presentation on Tuesday, February 18th at 11:30 AM ET –

Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

BOTHELL, WA, Feb.  03, 2020  (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the closing of its registered direct offering with two institutional investors for 3,492,063 shares of common stock. All of the common stock was sold at $0.63 per share for gross proceeds to the Company totaling approximately $2.2 million, before deducting placement agent commissions and expenses. Cocrystal intends to use the net proceeds from the offering for working capital and other general corporate purposes.

COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING

BOTHELL, WA, Jan.  29, 2020  (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of a registered direct offering with gross proceeds to the Company expected to be approximately $2.2 million before deducting placement agent commissions and expenses. The proposed offering equates to 3,492,063 shares of common stock at $0.63 per share. The Company intends to use the net proceeds for working capital and other general corporate purposes.

COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING

– Presentation on Tuesday, December 10th at 4:40 pm PST –

Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

News for Cocrystal Pharma Stock (COCP)